Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Bills for Amended PAL Submitted to the Diet
April 15, 2002
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
April 15, 2002
- Korosho Details 5-year Plan for Policy Evaluation
April 15, 2002
- DIAGNOSTIC NEWS IN BRIEF
April 15, 2002
- Cost Calculation Method Needs Improvements: Budget Committee
April 15, 2002
- Korosho Prepares Decision Tree for Medical Devices
April 15, 2002
- Fuso Ties Up with GAL PHARMA for Cancer Diagnostic Products
April 8, 2002
- Fee Is Necessary to Ensure Cooperation in Immediate PMS: Survey
April 8, 2002
- WORLD NEWS IN BRIEF
April 8, 2002
- Teijin Stops Shipment of Blood Glucose Self-measuring Device
April 8, 2002
- Fukujin to Upgrade Customer Support Services
April 8, 2002
- Terumo: New Pump Data Management System
April 8, 2002
- Cancer Detected, Suspected in 38,873 Individuals: Municipal Cancer Examinations
April 8, 2002
- JV for Animal Health by BI, Shionogi, Starts Operation
April 8, 2002
- Terumo Obtains Marketing Rights for Portable Insulin Pump
April 8, 2002
- Sleep Disorders Discussed: Fujisawa, Sanofi-Synthelabo Seminar
April 8, 2002
- Korosho Announces New Research Projects for FY2002
April 8, 2002
- Yamanouchi to Nearly Achieve 6% Market Share: President Takenaka
April 8, 2002
- FY2002 Budget Approved by Diet
April 8, 2002
- Takeda Subscribes to Gene Logic's Gene Expression Database
April 8, 2002
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…